<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833218</url>
  </required_header>
  <id_info>
    <org_study_id>389:1/2020</org_study_id>
    <nct_id>NCT04833218</nct_id>
  </id_info>
  <brief_title>Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury</brief_title>
  <official_title>Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluation of the effect of Propranolol versus propranolol and clonidine on decreasing&#xD;
      sympathetic hyperactivity after moderate traumatic brain injury&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      measuring catecholamine levels after moderate traumatic brain injury after giving propranolol&#xD;
      and clonidine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catecholamine level on day 7</measure>
    <time_frame>seven days</time_frame>
    <description>measuring catecholamine level on day 7 after giving study drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean arterial blood pressure every 4 hours herat rate every 4 hours temperature every 4 hours respiratory rate every 4 hours</measure>
    <time_frame>7 days</time_frame>
    <description>measuring hemodynamics every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glascow coma scale</measure>
    <time_frame>7 days</time_frame>
    <description>measuring glascow coma scale twice daily between 9 and 12 and higher score means better outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>propranolol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we will give propranolol 40 milligram tablet twice daily in orogastric or nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propranolol clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we will give propranolol 20 milligram tablet twice daily and clonidine 150 microgram tablet twice daily in orogatric or nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>we will give conventional treatment, no propranolol nor clonidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Test of catecholamines level in moderate traumatic brain injury</description>
    <arm_group_label>propranolol clonidine</arm_group_label>
    <arm_group_label>propranolol group</arm_group_label>
    <other_name>Clonidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GCS on admission between 9 and 12 age 18 up to 60 years both sexes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of heart disease, cardiac arrhythmia and myocardial infarction diagnosis&#xD;
             ofpreexisting brain dysfunction. impending brain herniation and craniotomy diagnosis&#xD;
             of spinal cord injuries. diagnisis of severe liver and renal disease current use of&#xD;
             beta blocker and or alpha agonist current using of intravenous vasopressor&#xD;
             contraindication to enteral feeding and can not swallow pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amany Khairy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Of Medicine</name>
      <address>
        <city>Minya</city>
        <zip>61111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Fatma Rabea Mohammed</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

